Dr. Mehrdad Abedi

Dr. Abedi is a professor of medicine at UC Davis Health and a nationally recognized leader in hematologic oncology, where he pioneers curative strategies for patients with high-risk and treatment-refractory blood cancers. As director of stem cell transplantation and cellular therapy programs, he integrates autologous and allogeneic transplants with next-generation immunotherapies, including CAR-T cells and engineered donor lymphocytes. His approach personalizes each therapeutic course by aligning cellular strategies with the disease’s molecular signature. Patients receive continuous, hands-on support throughout their treatment journey, from preparative regimens to long-term survivorship care. Keywords such as “blood cancer specialist,” “CAR-T therapy Sacramento,” and “stem cell transplant UC Davis” increase discoverability for individuals seeking advanced treatment options in Northern California.

At the UC Davis Comprehensive Cancer Center, Dr. Abedi leads a multidisciplinary care model where hematopathologists, radiation oncologists, immunogeneticists, transplant pharmacists, and supportive care teams collaborate on tailored treatment pathways. Weekly conferences align diagnostic findings with therapeutic goals, ensuring each patient receives a data-driven plan adapted to evolving clinical needs. The integration of psychosocial support, nutritional counseling, and survivorship planning reflects his holistic philosophy. Coordinated nursing and pharmacy teams monitor patients across the transplant timeline, emphasizing safety, symptom control, and quality of life. This collaborative infrastructure allows patients to navigate complex treatments within a unified and compassionate system.

Dr. Abedi’s translational research explores how hematopoietic stem cell behavior and immune cell interactions govern outcomes in transplant and immunotherapy settings. His laboratory investigates the mechanisms underlying graft-versus-tumor effects, immune escape, and chronic graft-versus-host disease. These insights guide early-phase clinical trials aimed at modulating the marrow microenvironment and enhancing post-transplant immune surveillance. Collaborations with statewide consortia and national partners allow rapid translation of research into novel therapeutic protocols. Patients participating in these studies contribute to real-time discoveries that inform future standards of care. Keywords such as “graft-versus-leukemia research,” “GVHD prevention,” and “stem cell immunotherapy” highlight Dr. Abedi’s scientific contributions and clinical innovations.